IMMUNOGEN, INC. 
By NEW YORK, January 7, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Mallinckrodt plc (NYSE: MNK), Haemonetics Corporation (NYSE: HAE), Select Medical Holdings Corporation (NYSE: SEM), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Mallinckrodt plc Research Report
On January 2, 2014, Mallinckrodt plc (Mallinckrodt) announced its participation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. The Company informed that Mallinckrodt's President and CEO, Mark Trudeau, is scheduled to make the presentation on January 15, 2014 at 2:30 p.m. PST / 5:30 p.m. EST. The Full Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/24f6_MNK
--
Haemonetics Corporation Research Report
On January 2, 2014, Haemonetics Corporation (Haemonetics) announced that it will participate at the 32nd Annual J.P. Morgan Health Conference in San Francisco. The Company stated that Haemonetics' President and CEO, Brian Concannon, is scheduled to make a presentation on January 15, 2014 at 10:00 a.m. PT / 1:00 p.m. ET. According to the Company, interested parties can access a live webcast of Mr. Concannon's presentation via a link given in the website of the Company. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/7c61_HAE
--
Select Medical Holdings Corporation Research Report
On December 23, 2013, Select Medical Holdings Corporation (Select Medical) announced that its Board of Directors has appointed David S. Chernow as the President and CEO of the Company, effective from January 1, 2014. The Company notified that Chernow has served as the Company's President since September 2010. Additionally, the Board reported the appointments of Robert A. Ortenzio to serve as the Company's Executive Chairman and Co-Founder, as well as that of Rocco A. Ortenzio as the Company's Vice Chairman and Co-Founder, effective from January 1, 2014. The Full Research Report on Select Medical Holdings Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/8287_SEM
--
Horizon Pharma, Inc. Research Report
On January 2, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced the availability of Horizon-labeled VIMOVO (naproxen/esomeprazole magnesium) tablets in US, for the relief of signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drug (NSAIDs). The Company informed that it expects to launch Horizon-labeled VIMOVO commercially with its primary care sales force on February 3, 2014. "The availability of Horizon-labeled VIMOVO is a major milestone for us as we plan for our full commercial launch. We expect to complete hiring and training our expanded sales force this month and commence our launch of VIMOVO in early February," said Timothy P. Walbert, Chairman, President, and CEO of Horizon Pharma. "Effective today, VIMOVO is now available via our co-pay program and is also included in our Prescriptions-Made-Easy specialty pharmacy program, ensuring VIMOVO is available at a reasonable out-of-pocket cost to patients." The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/05ea_HZNP
--
ImmunoGen, Inc. Research Report
On December 30, 2013, ImmunoGen, Inc. (ImmunoGen) announced the appointment of David Johnston as the Company's Executive Vice President and CFO, with immediate effect. The Company stated that in his new role, David will report to Daniel Junius, President and CEO of ImmunoGen. Prior to joining the Company, Johnston served as CFO at AVEO Pharmaceuticals , Inc. "I am delighted to have Dave join ImmunoGen," said Mr. Junius. "His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the Company to our next stages." The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/11c8_IMGN
----
EDITOR NOTES:
1) This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2) Information in this release is fact checked and produced on a best efforts
basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or omissions, please notify
us below.
3) This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the investing
public.
4) If you wish to have your company covered in more detail by our team, or wish
to learn more about our services, please contact us at
pubco@EquityNewsNetwork.com.
5) For any urgent concerns or inquiries, please contact us at
compliance@EquityNewsNetwork.com.
6) Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to research@EquityNewsNetwork.com for
consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
